Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Reinhard Glueck"'
Autor:
Shrikant Sharma, Veer Bahadur Singh, Sanjay Kumar, Vipul Prajapati, Jitendra Patel, Rajesh Vukkala, Sanjay Kumar Jangid, Jayesh Sanmukhani, Gaurav Gupta, Pradip Patel, Ravindra Mittal, Reinhard Glueck
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 14, Iss 6, Pp 1362-1369 (2018)
This phase II / III clinical trial was conducted to evaluate the immunogenicity and safety of the Tetravalent Influenza vaccine (Split virion) I.P. (TetIV) developed indigenously in the country for the first time by M/s Cadila Healthcare Limited, Ind
Externí odkaz:
https://doaj.org/article/b3c336df68fa4446be4c57f90ba70fb3
Autor:
Laura Fernández, Jose Carlos Solana, Carmen Sánchez, Mª Ángeles Jiménez, Jose M. Requena, Rhea Coler, Steven G. Reed, Jesus G. Valenzuela, Shaden Kamhawi, Fabiano Oliveira, Epifanio Fichera, Reinhard Glueck, Maria Elena Bottazzi, Gaurav Gupta, Pedro Cecilio, Begoña Pérez-Cabezas, Anabela Cordeiro-da-Silva, Luigi Gradoni, Eugenia Carrillo, Javier Moreno
Publikováno v:
Microorganisms, Vol 9, Iss 11, p 2253 (2021)
Visceral leishmaniasis (VL) is the most severe clinical form of leishmaniasis, fatal if untreated. Vaccination is the most cost-effective approach to disease control; however, to date, no vaccines against human VL have been made available. This work
Externí odkaz:
https://doaj.org/article/117c18657fb5436286218190c48f7d64
Autor:
Ashwani Sood, Monjori Mitra, Himanshu Arvind Joshi, Uma Siddhartha Nayak, Prashanth Siddaiah, T. Ramesh Babu, Samarendra Mahapatro, Jayesh Sanmukhani, Gaurav Gupta, Ravindra Mittal, Reinhard Glueck
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 13, Iss 7, Pp 1523-1530 (2017)
This phase III clinical trial was conducted to evaluate the immunogenicity and safety of the single-dose and multi-dose formulations of a novel MMR vaccine (live, freeze-dried) developed by M/s Cadila Healthcare Limited, India (Cadila MMR vaccine), c
Externí odkaz:
https://doaj.org/article/b9ae060bc0ff4ee48c1371088e2ac6db
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 13, Iss 6, Pp 1421-1424 (2017)
The discovery of HPV as the etiological factor for HPV-associated malignancies and disease has opened up several opportunities for prevention and therapy. Current commercially available HPV vaccines (Gardasil, Gardasil 9, and Cervarix) are prophylact
Externí odkaz:
https://doaj.org/article/abdf78510bb644c69e91e6dc0ab80d8f
Autor:
Pedro Cecílio, Begoña Pérez-Cabezas, Laura Fernández, Javier Moreno, Eugenia Carrillo, José M Requena, Epifanio Fichera, Steven G Reed, Rhea N Coler, Shaden Kamhawi, Fabiano Oliveira, Jesus G Valenzuela, Luigi Gradoni, Reinhard Glueck, Gaurav Gupta, Anabela Cordeiro-da-Silva
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 11, Iss 11, p e0005951 (2017)
The notion that previous infection by Leishmania spp. in endemic areas leads to robust anti-Leishmania immunity, supports vaccination as a potentially effective approach to prevent disease development. Nevertheless, to date there is no vaccine availa
Externí odkaz:
https://doaj.org/article/4dbf67c497bc458e843402a993d070cb
Autor:
Anabela Cordeiro-da-Silva, Jesus G. Valenzuela, Laura Fernández, Mª Ángeles Jiménez, Epifanio Fichera, Gaurav Gupta, Begoña Pérez-Cabezas, Maria Elena Bottazzi, Carmen Sánchez, Reinhard Glueck, Pedro Cecílio, Eugenia Carrillo, Fabiano Oliveira, Rhea N. Coler, Reed Steven G, Shaden Kamhawi, Javier Moreno, Luigi Gradoni, José Carlos Solana, Jose M. Requena
Publikováno v:
Microorganisms
Digital.CSIC. Repositorio Institucional del CSIC
instname
Microorganisms, Vol 9, Iss 2253, p 2253 (2021)
Repisalud
Instituto de Salud Carlos III (ISCIII)
Volume 9
Issue 11
Digital.CSIC. Repositorio Institucional del CSIC
instname
Microorganisms, Vol 9, Iss 2253, p 2253 (2021)
Repisalud
Instituto de Salud Carlos III (ISCIII)
Volume 9
Issue 11
Visceral leishmaniasis (VL) is the most severe clinical form of leishmaniasis, fatal if untreated. Vaccination is the most cost-effective approach to disease control; however, to date, no vaccines against human VL have been made available. This work
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3c417afd845f912fe808c46121da5bc
http://hdl.handle.net/10261/268459
http://hdl.handle.net/10261/268459
Autor:
Sanjay Kumar Jangid, Rajesh Vukkala, S. P. Sharma, Reinhard Glueck, Gaurav Gupta, Jitendra P Patel, Ravindra Mittal, Veer Bahadur Singh, Jayesh Sanmukhani, Pradip Patel, Vipul Prajapati, Sanjay Kumar
Publikováno v:
Human Vaccines & Immunotherapeutics
This phase II / III clinical trial was conducted to evaluate the immunogenicity and safety of the Tetravalent Influenza vaccine (Split virion) I.P. (TetIV) developed indigenously in the country for the first time by M/s Cadila Healthcare Limited, Ind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a64482c41fe7cfe6181bc8c0bc66287e
https://doi.org/10.1080/21645515.2018.1441654
https://doi.org/10.1080/21645515.2018.1441654
Publikováno v:
Human Vaccines & Immunotherapeutics. 13:1421-1424
The discovery of HPV as the etiological factor for HPV-associated malignancies and disease has opened up several opportunities for prevention and therapy. Current commercially available HPV vaccines (Gardasil, Gardasil 9, and Cervarix) are prophylact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92fe96cd81f00ff73cc605a1de6c7b46
https://doi.org/10.1080/21645515.2017.1289301
https://doi.org/10.1080/21645515.2017.1289301
Autor:
Jayesh Sanmukhani, Uma Siddhartha Nayak, Himanshu Arvind Joshi, Ravindra Mittal, Prashanth Siddaiah, Samarendra Mahapatro, Ashwani Sood, Monjori Mitra, Gaurav Gupta, T Ramesh Babu, Reinhard Glueck
Publikováno v:
Human Vaccines & Immunotherapeutics
This phase III clinical trial was conducted to evaluate the immunogenicity and safety of the single-dose and multi-dose formulations of a novel MMR vaccine (live, freeze-dried) developed by M/s Cadila Healthcare Limited, India (Cadila MMR vaccine), c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd744918f2452e65d8a232baf245cfc3
https://doi.org/10.1080/21645515.2017.1302629
https://doi.org/10.1080/21645515.2017.1302629
Publikováno v:
Vaccine
Highlights • Affordable, safe & potent Measles vectored HPV vaccine developed & compared. • This vaccine found immunogenic similar to classical HPV protein vaccine from Pichia. • It can be given as childhood vaccine at 9–12 months of age like
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae8aa57f41049c8f0c70fa3795d47296
https://doi.org/10.1016/j.vaccine.2016.07.051
https://doi.org/10.1016/j.vaccine.2016.07.051